First Trust Advisors’s abrdn Life Sciences Investors HQL Stock Holding History

First Trust Advisors’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$933K	Buy	57,337 +8,567	+18%	+$143K	﹤0.01%	2176
2025 Q4	$818K	Buy	48,770 +1,880	+4%	+$31.6K	﹤0.01%	2216
2025 Q3	$727K	Buy	46,890 +11,569	+33%	+$158K	﹤0.01%	2212
2025 Q2	$452K	Buy	35,321 +18,674	+112%	+$230K	﹤0.01%	2298
2025 Q1	$211K	Buy	16,647 +3,289	+25%	+$44.5K	﹤0.01%	2452
2024 Q4	$175K	Buy	13,358 +483	+4%	+$6.97K	﹤0.01%	2490
2024 Q3	$194K	Buy	12,875 +513	+4%	+$7.76K	﹤0.01%	2317
2024 Q2	$175K	Buy	12,362 +1,914	+18%	+$25.9K	﹤0.01%	2265
2024 Q1	$142K	Buy	+10,448	New	+$145K	﹤0.01%	2301
2023 Q4	–	Sell	-10,547	Closed	-$132K	–	2382
2023 Q3	$132K	Buy	+10,547	New	+$139K	﹤0.01%	2319
2023 Q1	–	Sell	-17,060	Closed	-$242K	–	2410
2022 Q4	$242K	Hold	17,060	–	–	﹤0.01%	2342
2022 Q3	$233K	Sell	17,060 -1,308	-7%	-$19.5K	﹤0.01%	2378
2022 Q2	$261K	Sell	18,368 -654	-3%	-$9.88K	﹤0.01%	2333
2022 Q1	$315K	Sell	19,022 -1,962	-9%	-$33.8K	﹤0.01%	2364
2021 Q4	$404K	Buy	20,984 +675	+3%	+$13.6K	﹤0.01%	2340
2021 Q3	$422K	Buy	20,309 +1,350	+7%	+$28.9K	﹤0.01%	2321
2021 Q2	$406K	Buy	18,959 +675	+4%	+$13.6K	﹤0.01%	2322
2021 Q1	$360K	Sell	18,284 -2,025	-10%	-$41.7K	﹤0.01%	2296
2020 Q4	$401K	Sell	20,309 -1,350	-6%	-$25K	﹤0.01%	2168
2020 Q3	$381K	Sell	21,659 -1,350	-6%	-$24.2K	﹤0.01%	2110
2020 Q2	$413K	Hold	23,009	–	–	﹤0.01%	2072
2020 Q1	$345K	Sell	23,009 -2,700	-11%	-$44.2K	﹤0.01%	2051
2019 Q4	$448K	Buy	25,709 +2,700	+12%	+$44.3K	﹤0.01%	2148
2019 Q3	$347K	Buy	23,009 +3,541	+18%	+$56.7K	﹤0.01%	2249
2019 Q2	$328K	Buy	+19,468	New	+$321K	﹤0.01%	2268
2017 Q1	–	Sell	-56,029	Closed	-$952K	–	2415
2016 Q4	$952K	Buy	56,029 +5,120	+10%	+$89.9K	﹤0.01%	1848
2016 Q3	$954K	Sell	50,909 -6,835	-12%	-$129K	﹤0.01%	1739
2016 Q2	$993K	Sell	57,744 -28,136	-33%	-$519K	﹤0.01%	1701
2016 Q1	$1.54M	Buy	85,880 +1,096	+1%	+$19.9K	0.01%	1443
2015 Q4	$2M	Sell	84,784 -2,221	-3%	-$55.1K	0.01%	1392
2015 Q3	$1.96M	Buy	87,005 +15,984	+23%	+$448K	0.01%	1405
2015 Q2	$2M	Buy	71,021 +17,554	+33%	+$487K	0.01%	1538
2015 Q1	$1.47M	Sell	53,467 -10,383	-16%	-$283K	﹤0.01%	1603
2014 Q4	$1.59M	Buy	63,850 +3,707	+6%	+$89K	0.01%	1565
2014 Q3	$1.33M	Buy	+60,143	New	+$1.31M	0.01%	1590
2014 Q2	–	Sell	-51,437	Closed	-$1.12M	–	2246
2014 Q1	$1.12M	Sell	51,437 -4,835	-9%	-$108K	﹤0.01%	1637
2013 Q4	$1.15M	Buy	56,272 +8,527	+18%	+$165K	0.01%	1582
2013 Q3	$919K	Buy	47,745 +3,842	+9%	+$73.6K	0.01%	1591
2013 Q2	$785K	Buy	+43,903	New	+$793K	0.01%	1574

Other funds holding HQL

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

First Trust Advisors's HQL Position: Q1 2026 in Review

First Trust Advisors increased its abrdn Life Sciences Investors (HQL) stake by 18% in Q1 2026, buying an estimated $143K and bringing the position to 57,337 shares worth $933K. The position accounts for ﹤0.01% of the portfolio, ranked #2176.

First Trust Advisors first reported a position in HQL in Q2 2013 and has held it in 39 quarters since. The position peaked at $2M in Q4 2015. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.

First Trust Advisors held 57,337 shares of abrdn Life Sciences Investors worth $933K as of Q1 2026.
First Trust Advisors bought 8,567 abrdn Life Sciences Investors shares in Q1 2026, an estimated $143K.
abrdn Life Sciences Investors made up ﹤0.01% of First Trust Advisors's portfolio in Q1 2026, its #2176 holding.
First Trust Advisors first reported a position in abrdn Life Sciences Investors in Q2 2013 and has held it in 39 quarters since.
First Trust Advisors's abrdn Life Sciences Investors position peaked at $2M in Q4 2015.
86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.

Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.